NCI (US National Cancer Institute) seeks partner to develop oesophageal cell sampler:
This article was originally published in Clinica
Executive Summary
The US National Cancer Institute (NCI) is looking for a partner to help it develop and commercialise a better method of obtaining cell samples from the oesophagus for cancer screening. Cytologic samples are currently gathered using an inflatable balloon or an encapsulated sponge. The technique is poor at picking up early signs of cancer and needs to be improved, says the NCI. The cooperative research and development agreement is expected to last four years.
You may also be interested in...
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.